

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A ~~non-aqueous liquid~~ rapid distribution pharmaceutical composition ~~comprising~~ consisting of a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous carrier; said vehicle having stably dispersed therein an antibacterial substance in an antibacterially effective amount[~~[.]~~] wherein wherein the antibacterial substance is a cephalosporin selected from the group consisting of ceftiofur and salts thereof, cephalixin, cephradine, cefquinome, cephacetrile, cephalonium, cefuroxime, cefazidime, cefoperazone, sodium cephemethcarboxylate, cephem heptahydrate, cephalosporin di- and tri-hydrate, cephadroxil monohydrate, cephalozin sodium monohydrate, cefiximine, ceftaxime, ceftizoxime, ceftriaxone, o-formylcefamandole, salts of 3-acetoxymethyl-7-(iminocetamido)-cephalosporanic acid derivatives, monohydrate of 7-(D- $\alpha$ -amino- $\alpha$ -(p-hydroxyphenyl)acetamino)-3-methyl-3-cephem-1-carboxylic acid, hydrochloride salt of syn-7-((2-amino-1-thiazolyl)(methoxyimino)acetyl)-amino)-3-methyl-3-cephem-4-carboxylic acid, crystalline cephem acid addition salts, (pivaloyloxy)methyl-7-beta-(2-(2-amino-4-thiazolyl)acetamido)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylate, cephalixin, cephalixin monohydrate, 7-(D-2-naphthylglycylamino)-3-methyl-3-cephem-4-carboxylic acid tetrahydrate, tautomers, stereoisomers, enantiomers, salts, hydrates and prodrugs thereof, and combinations thereof.
2. (original) The composition of Claim 1 that is suitable for administration by intramammary infusion to an udder of a milk producing animal for treatment and/or prevention of a bacterial disease of the udder.
3. (original) The composition of Claim 2 wherein the bacterial disease is mastitis.

4. (original) The composition of Claim 1 that is suitable for otic administration for treatment and/or prevention of an infection of an ear.
- 5.-13. (cancelled)
14. (cancelled)
15. (original) The composition of Claim 1 wherein the antibacterial substance is selected from the group consisting of ceftiofur and pharmaceutically acceptable salts thereof, and combinations thereof.
16. (original) The composition of Claim 15 wherein the antibacterial substance is present at a concentration of about 1 to about 1000 mg/ml.
17. (original) The composition of Claim 15 wherein the antibacterial substance is present at a concentration of about 5 to about 750 mg/ml.
18. (original) The composition of Claim 15 wherein the antibacterial substance is present at a concentration of about 10 to about 100 mg/ml.
19. (original) The composition of Claim 1 wherein the antibacterial substance is ceftiofur hydrochloride.
20. (original) The composition of Claim 1 wherein the antibacterial substance is ceftiofur crystalline free acid.
21. (original) The composition of Claim 1 wherein the amphipathic oil is a polyglycolized glyceride prepared by an alcoholysis reaction of natural triglycerides with polyethylene glycols.
22. (cancelled)
23. (original) The composition of Claim 21 wherein the polyglycolized glyceride comprises a main fatty acid component of oleic acid or linoleic acid.

24. (original) The composition of Claim 21 wherein the polyglycolized glyceride comprises a main fatty acid component of oleic acid.
25. (previously presented) The composition of Claim 21 wherein the polyglycolized glyceride is peglicol 5-oleate.
26. (original) The composition of Claim 1 wherein the non-aqueous carrier is selected from the group consisting of vegetable oils, mineral oils, medium to long chain fatty acids and alkyl esters thereof, propylene glycol di-esters of medium to long chain fatty acids, mono-, di-, and triglyceryl esters of fatty acids, polyethylene glycols, and combinations thereof.
27. (original) The composition of Claim 1 wherein the non-aqueous carrier is a vegetable oil selected from the group consisting of cottonseed oil, corn oil, sesame oil, soybean oil, olive oil, coconut oil, fractionated coconut oils, peanut oil, sunflower oil, safflower oil, almond oil, avocado oil, palm oil, palm kernel oil, babassu oil, beechnut oil, linseed oil, rape oil and combinations thereof.
28. (original) The composition of Claim 1 wherein the non-aqueous carrier is cottonseed oil.
29. (cancelled)
30. (original) The composition of Claim 1 wherein the amphipathic oil constitutes about 0.01% to about 99% weight/volume of the composition.
31. (original) The composition of Claim 1 wherein the amphipathic oil constitutes about 1% to about 80% weight/volume of the composition.
32. (original) The composition of Claim 1 wherein the amphipathic oil constitutes about 3% to about 25% weight/volume of the composition.
33. (original) The composition of Claim 1 wherein the microcrystalline wax constitutes about 0.01% to about 50% weight/volume of the composition.

- 34. (original) The composition of Claim 1 wherein the microcrystalline wax constitutes about 1% to about 40% weight/volume of the composition.
- 35. (original) The composition of Claim 1 wherein the microcrystalline wax constitutes about 3% to about 15% weight/volume of the composition.
- 36. (original) The composition of Claim 1 wherein the non-aqueous carrier constitutes about 0.5% to about 99% weight/volume of the composition.
- 37. (original) The composition of Claim 1 wherein the non-aqueous carrier constitutes about 10% to about 95% weight/volume of the composition.
- 38. (original) The composition of Claim 1 wherein the non-aqueous carrier constitutes about 40% to about 90% weight/volume of the composition.
- 39. (original) The composition of Claim 1 that further comprises at least one excipient selected from the group consisting of antioxidants, preservatives, stabilizers, wetting agents, lubricants, emulsifiers, salts for influencing osmotic pressure, coloring agents, alcohols and buffering agents.
- 40. (original) The composition of Claim 1 that further comprises at least one excipient selected from the group consisting of tocopherols, ascorbyl palmitate, butyl hydroxyanisole, butyl hydroxytoluene, benzoic acid and derivatives thereof, ethylenediamine, sodium bisulfite, sulfur dioxide, maleic acid, propyl gallate, magnesium stearate, talc, silicic acid and carbohydrates.
- 41-48. (cancelled)
- 49. (new) A rapid distribution pharmaceutical composition comprising
  - (a) Labrafil™ M1944CS, (b) microcrystalline wax, and (c) cottonseed oil, and (d) cefixime hydrochloride.